CN1241192A - Pro-drugs and counterparts of camptothecin, their application as medicines - Google Patents

Abstract

The invention concerns novel counterparts of camptothecin and in particular products complying with the following formulae: 8-ethyl-8,9-dihydro-8-hydroxy-1-benzyl-2H, 10H, 12H-[1,3]oxazino[5,6-f]oxepino[3',4':6,7]indolizino[1,2-b]quinolein-10,13(15H)-dione; 5-ethyl-9,10-difluoro-4,5-dihydro-5-(2-amino-1-oxoethoxy)-1H-oxepino[3',4':6,7]indolizino[1,2-b]quinolein-3,15(4H,13H)-dione; 5-ethyl-9,10-difluoro-4,5-dihydro-5-(2-amino-1-oxopropoxy)-1H-oxepino[3',4':6,7]indolizino[1,2-b]quinolein-3,15(4H,13H)-dione. The invention also concerns their method of preparation, their application as medicines, the pharmaceutical compositions containing them and their use in producing tumoricidal, antiviral and parasiticide medicines.

Description

The prodrug forms of camptothecine and analogue, and pharmaceutical use

Camptothecine is a natural compounds, separates (seeing Wall etc., J.Amer.Chem.Soc.88:3888 (1966)) first from the leaf of Chinese plant camptotheca acuminata and bark.Camptothecine is to condense the pentacyclic compound that forms by indolizino [1,2-b] quinoline segment (ring A, B, C and D) and the Alpha-hydroxy lactone with six-ring (ring E).Have alpha-hydroxy 20 carbon and be asymmetric and brought rotatory power for this molecule.The natural form of camptothecine has absolute " S " configuration and is shown below on 20 carbon:

Camptothecine and analogue thereof have antiproliferative activity to some cancer cell cordings, and these clones comprise human tumor cell line (Suffness, the M etc. of colon, lung and mammary gland, " alkaloid chemistry and pharmacology ", Bross A etc., Vol.25, the 73rd page (Acedemic Press, 1985)).This antiproliferative activity that shows camptothecine is relevant with its inhibition activity to the DNA topoisomerase I.

In addition, camptothecine and some analogue thereof are water insoluble, and this brings difficulty to them by the parenteral route administration.The soluble derivative that has prepared camptothecine, their A and B endless belt have salifiable substituting group (referring to, for example, US 4,981,968, US 5,049,668, EP 540,099).But the anti-tumor activity that these products demonstrate is lower than water-insoluble derivative.Other soluble derivative that has also prepared camptothecine, but wherein 20 hydroxyl had the acid of salt forming group such as glycine esterification (referring to, US 4943579 and PCT WO96/02546).Those skilled in the art are called " prodrug forms " with these derivatives, because their lifeless matter activity own, and just when using, after metabolism first, could produce active to the patient.In animal body and shown that clinically the prodrug forms of the Alpha-hydroxy lactone analogue of camptothecine has good anti-tumor effect, but be attended by destructive side effect, serious diarrhoea for example occurs, bring danger for patient's life.Therefore, need the camptothecine water-soluble analogues that exploitation is more effective and can tolerate better.

Moreover, clear and definite Alpha-hydroxy lactone in the camptothecine body and external activity all be essential (" camptothecine: new antitumor and anticancer agent ", Putmesil, volumes such as M, the 27th page (CRC press, 1995); Wall M etc., " cancer research " 55:753 (1995); Hertzberg etc., " pharmaceutical chemistry magazine " 32:715 (1982) and Crow etc., " pharmaceutical chemistry magazine " 35:4160 (1992)).Yet, the beta-hydroxy lactone that the applicant finds to have 7 yuan of rings have with the Alpha-hydroxy lactone quite or than its bigger biological activity (unexposed PCT applies for FR96/00980).The present invention relates to the new derivative of camptothecin analogues, wherein 7 yuan of beta-hydroxy lactones have replaced the natural Alpha-hydroxy lactone of camptothecine.The beta-hydroxy lactone refers to contain between carboxyl carbon in this Alpha-hydroxy lactone and the hydroxyl alpha-carbon lactone of another carbon atom.

For the water-soluble that increases this camptothecin analogues selected two kinds of ways are arranged: on the A ring that the one kind is grafted to oxazine molecule, and second kind designed prodrug forms by the hydroxy functional group acylations with the beta-hydroxy lactone.

Specifically, in this type of new camptothecin analogues, compound of the present invention is for to modify the analogue that obtains by Jia Ru oxazine ring on carbon 10 and 11, or the beta-hydroxy lactone prodrug forms that replaces the natural Alpha-hydroxy lactone of camptothecine to obtain wherein.Therefore, compound of the present invention is the camptothecine beta-hydroxy lactone analogue or the water-soluble prodrug of wherein Jie Zhi You oxazine ring and has the unexpected strong biological activity in this area.

More particularly, theme of the present invention is any mixture or its pharmaceutical salts of compound, its racemic modification, enantiomeric forms or these forms of formula (I) and formula (II):

R ₁Expression low alkyl group, low-grade alkenyl, alkynyl of low-grade chain, low-grade halogenated alkyl, lower alkoxy low alkyl group or lower alkylthio low alkyl group;

R ₂, R ₃And R ₄Represent H, halogen, low-grade halogenated alkyl, low alkyl group, low-grade alkenyl, cyano group, rudimentary cyano group alkyl, nitro, rudimentary 4-nitro alkyl, amido, rudimentary amidoalkyl, diazanyl, rudimentary diazanyl alkyl, azido-, rudimentary azido-alkyl, (CH independently ₂) _mNR ₆R ₇, (CH ₂) _mOR ₆, (CH ₂) _mSR ₆, (CH ₂) _mCO ₂R ₆, (CH ₂) _mNR ₆C (O) R ₈, (CH ₂) _mC (O) R ₈, (CH ₂) _mOC (O) R ₈, O (CH ₂) _mNR ₆R ₇, OC (O) NR ₆R ₇, OC (O) (CH ₂) _mCO ₂R ₆Or (CH ₂) _n[N=X], OC (O) [N=X], (CH ₂) _mOC (O) [N=X] (in the present invention, 4 to 7 yuan of heterocyclic radicals of [N=X] expression nitrogen atom N, N is an atom of heterocyclic group, and X represents to constitute all the other atoms of these heterocycle needs, and they are selected from O, S, CH ₂, CH, N, NR ₉And COR ₁₀), do not replace or be substituted the aryl or the lower aryl alkyl of (promptly replace one to four time) on aryl or heterocycle, wherein substituting group is low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group, perhaps R ₂And R ₃Or R ₃And R ₄Form 3 or 4 yuan chain together, wherein the element of this chain is selected from CH, CH ₂, O, S, N or NR ₉

R ₅Expression H, halogen, low-grade halogenated alkyl, low alkyl group, lower alkoxy, lower alkoxy low alkyl group, lower alkylthio low alkyl group, cycloalkyl, cycloalkyl low-grade alkyl, cyano group, cyano group alkyl, the rudimentary alkylsulfonyl alkyl of low alkyl group, rudimentary hydroxyalkyl, nitro, (CH ₂) _mC (O) R ₈, (CH ₂) _mNR ₆C (O) R ₈, (CH ₂) _mNR ₆R ₇, (CH ₂) _mN (CH ₃) (CH ₂) _nNR ₆R ₇, (CH ₂) _mOC (O) R ₈, (CH ₂) _mOC (O) NR ₆R ₇, (CH ₂) _mS (O) ₉R ₁₁, (CH ₂) _mP (O) R ₁₂R ₁₃, (CH ₂) ₂P (S) R ₁₂R ₁₃Or (CH ₂) _n[N=X], OC (O) [N=X], (CH ₂) _mOC (O) [N=X], do not replace or substituted (promptly replacing one to four time on aryl or heteroaryl) aryl or lower aryl alkyl, wherein substituting group is low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

R ₆And R ₇Represent H, low alkyl group, rudimentary hydroxyalkyl, the rudimentary aminoalkyl group of low alkyl group, rudimentary aminoalkyl group, cycloalkyl, cycloalkyl low-grade alkyl, low-grade alkenyl, lower alkoxy low alkyl group, low-grade halogenated alkyl independently or be substituted (promptly replacing one to four time) or unsubstituted aryl or lower aryl alkyl on aryl, wherein substituting group is low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

R ₈Represent H, low alkyl group, rudimentary hydroxyalkyl, amino, low-grade alkyl amino, the rudimentary aminoalkyl group of low alkyl group, rudimentary aminoalkyl group, cycloalkyl, cycloalkyl low-grade alkyl, low-grade alkenyl, lower alkoxy, lower alkoxy low alkyl group, low-grade halogenated alkyl or be substituted (promptly replacing one to four time) or unsubstituted aryl or lower aryl alkyl on aryl, wherein substituting group is low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

R ₉Expression H, low alkyl group, low-grade halogenated alkyl, aryl or the aryl that is replaced by following one or more groups: low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

R ₁₀Expression H, low alkyl group, low-grade halogenated alkyl, lower alkoxy, aryl or the aryl (one to four substituting group is promptly arranged on aryl) that is replaced by one or more groups, substituting group is selected from low alkyl group, low-grade halogenated alkyl, rudimentary hydroxyalkyl or lower alkoxy low alkyl group;

R ₁₁Expression low alkyl group, aryl, (CH ₂) _mOR ₁₄, (CH ₂) _mSR ₁₄, (CH ₂) ₂NR ₁₄R ₁₅Or (CH ₂) _m[N=X];

R ₁₂And R ₁₃Represent low alkyl group, aryl, lower alkoxy, aryloxy or amino independently;

R ₁₄And R ₁₅Represent H, low alkyl group or aryl independently;

R ₁₆Expression H or OR ₂₁

R ₁₇Expression OR ₆Or NR ₆R ₇

R ₁₈And R ₁₉Represent H, halogen, low alkyl group, lower alkoxy or hydroxyl independently;

R ₂₀Expression H or halogen;

R ₂₁Expression H, low alkyl group, CHO or C (O) (CH ₂) _mCH ₃

R _pRepresent H or be easy to the cracked group, preferably corresponding to formula-C (O)-A-NR ₂₂R ₂₃Group, wherein A represents the straight or branched alkylidene group, this alkylidene group is determined on a case-by-case basis and is selected from free, esterification or salifiable hydroxyl, halogen, carboxyl free, esterification or salifiable, amino, list or dialkyl amido replace, and R ₂₂And R ₂₃Represent H, low alkyl group, rudimentary hydroxyalkyl, the rudimentary aminoalkyl group of low alkyl group, rudimentary aminoalkyl group, cycloalkyl, cycloalkyl low-grade alkyl, low-grade alkenyl, lower alkoxy low alkyl group, low-grade halogenated alkyl independently or do not replace or replace the aryl or the lower aryl alkyl of (one to four substituting group is promptly arranged) on aryl, substituting group is selected from low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

M is the integer between 0 to 6;

N is 1 or 2; And

Q represents 0 to 2 integer; And

[N=X] represents 4 to 7 yuan of heterocyclic radicals, and X represents to finish the chain of described heterocyclic radical needs and is selected from O, S, CH ₂, CH, N, NR ₉And COR ₁₀

Should understand and work as R _pWhen being hydrogen atom, R ₃And R ₄Form 3 or 4 yuan chain together.

In this article, the term " rudimentary " relevant with alkyl, alkylthio and alkoxyl group refers to contain the straight or branched saturated fatty hydrocarbyl group of 1 to 6 carbon atom, for example, methyl, ethyl, propyl group, sec.-propyl, butyl, the tertiary butyl, methylthio group, ethylmercapto group, methoxyl group and oxyethyl group.The term " rudimentary " relevant with term alkenyl or alkynyl group refers to contain 2 to 6 carbon atoms and the one or more pairs of keys or triple-linked group, for example, vinyl, allyl group, pseudoallyl, pentenyl, hexenyl, propenyl, ethynyl, proyl and butynyl.The term cycloalkyl is meant the ring that contains 3 to 7 carbon, for example, and cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.Term aryl refers to list, two or the tricyclic hydrocarbon compound, and wherein at least one ring is aromatic nucleus, and each ring contains maximum 7 carbon atoms, for example, and phenyl, naphthyl, anthryl, xenyl or indenyl.Term halogen refers to chlorine, bromine, iodine or fluorine.Corresponding to the term low-grade halogenated alkyl; rudimentary cyano group alkyl; rudimentary 4-nitro alkyl; rudimentary amidoalkyl; rudimentary diazanyl alkyl; rudimentary azido-alkyl; the lower aryl alkyl; rudimentary hydroxyalkyl; the lower alkoxy low alkyl group; the group of the rudimentary alkylsulfonyl alkyl of lower alkylthio low alkyl group and low alkyl group is respectively by one to three halogen; cyano group; nitro; amido; diazanyl; azido-; aryl; hydroxyl; low alkyl group; lower alkylthio or rudimentary alkylsulfonyl alkyl replace.Low-grade alkyl amino can contain one or two low alkyl group, for example represents NHCH ₃, NHCH ₂CH ₃, N (CH ₃) ₂Or N (CH ₃) (CH ₂CH ₃).Term free, esterification, etherificate or salifiable hydroxyl refers to OH, OCOR ₂₆, OR ₂₇Group and its alkoxide.

Compound of the present invention has two kinds of possible enantiomers, i.e. " R " and " S " configuration.The present invention includes these two kinds of enantiomeric forms and their mixture, comprise " RS " racemic mixture.For for simplicity, when the particular configuration do not pointed out in the structural formula, be interpreted as representing two enantiomers and composition thereof.

For prodrug forms of the present invention (R wherein _pBe not hydrogen atom), the product of preferred formula I.

As the example of the camptothecine of the replacement of initiator referring to United States Patent (USP) 4473692,4604463,4894956,5162532,5395939,5315007,5264579,5258516,5254690,5212317 and 5341745, PCT patent application US91/08028, US94/06451, US90/05172, US92/04611, US93/10987, US91/09598, EP94/03058 and EP95/00393 and european patent application 325247,495432,321122 and 540099.

This compounds that contains the oxazine ring:

-with the compound of the β hydroxy-lactone of general formula D: R wherein ₃Be hydroxyl, R ₄Be H and R ₁, R ₂, R ₅, R ₁₈, R ₁₉And R ₂₀Definition is as above handled under the Mannich reaction conditions to obtain the beta-hydroxy lactone compound of formula Ia with primary amine

R wherein ₁, R ₂, R ₅, R ₉, R ₁₈, R ₁₉And R ₂₀Definition as above.

This method comprises initiator in the presence of primary amine such as benzylamine, formaldehyde, in sour reagent such as acetate or propionic acid, is 30 to 80 ℃ of heating 0.5 to 5 hour in temperature.Perhaps, the Hexahydrotriazine that the acetic acid suspension of initiator and three-N-are replaced is as six hydrogen-1,3,5-trimethylammonium triazine, 1,3, and 5-triethyl Hexahydrotriazine or 1,3,5-tribenzyl Hexahydrotriazine are together 30 to 80 ℃ of heating 0.5 to 5 hour.

The open loop in alkaline medium that is determined on a case-by-case basis of the lactone of-general formula I a, so as after neutralization the compound of preparation formula IIa

R wherein ₁, R ₂, R ₅, R ₉, R ₁₇, R ₁₈, R ₁₉And R ₂₀Definition as above; R ₁₆Expression OR ₂₁, R wherein ₂₁Expression H or low alkyl group; And R ₁₇Expression OR ₆Or NHR ₆, and R ₆Expression H, low alkyl group, cycloalkyl, low alkyl group cycloalkyl, low-grade alkenyl, low alkyl group lower alkoxy or aryl or low-grade alkylaryl.

The compound of-described general formula D or the Ia acidylate that is determined on a case-by-case basis is preferably with definition C (O)-A-N-R as above ₂₂R ₂₃The derivative of group carries out the β hydroxy-lactone compound that acidylate prepares general formula I b, i.e. R _pIt or not the general formula I (prodrug forms of the present invention) of H.

-use the method identical can be with lactone Ib open loop with preparation alcohol acid IIb with open ring lactone Ia.

In aforesaid method, if desired can be according to standard guard method (Greene.T., " protecting group of organic synthesis " 10-86 (John Wiley ﹠amp; Sons 1981)) protection R ₂, R ₃, R ₄And R ₅Group.If R at least ₂₂And R ₂₃One in the group is H, or contain at least one with the inconsistent functional group of process for acylating chemistry as uncle or secondary amine, then need to use the protecting group that not influenced by acylation condition.Being generally used for protecting the protecting group of amine is tertbutyloxycarbonyl (BOC).Carry out acylation reaction then according to the method described above,, for example for BOC, pass through to handle with trifluoroacetic acid again with the protecting group cracking, thus preparation general formula (I) or compound (II).The use of protecting group be well known by persons skilled in the art (for example, can be referring to Greene.T., " protecting group of organic synthesis " John Wiley ﹠amp; Sons 1981).

The compound of formula D is as follows:

The compound of-formula M

R wherein ₁, R ₁₈And R ₁₉Definition as above and R ₂₀Expression H or halogen atom, with 2-halo-3-quinoline-methyl alcohol coupling of general formula N,

R wherein ₂, R ₃, R ₄And R ₅Definition as above and X represents halogen atom, thereby the compound of preparation formula O

R wherein ₁, R ₂, R ₃, R ₄, R ₅, R ₁₈, R ₁₉, R ₂₀Define as above with X;

-then the compound cyclization of general formula O is obtained defining the compound of general formula D as above.

In aforesaid method, if desired then can be according to standard guard method (Greene.T., " protecting group of organic synthesis " 10-86 (John Wiley ﹠amp; Sons 1981)) protection R ₁, R ₂, R ₃And R ₄Group.The reaction that is begun to form compound O by the compound of formula M and N can be carried out promptly so-called Mitsunobu reaction (referring to Mitsunobu, O. etc., " synthesizing ", page 1 (1981)) according to method known to those skilled in the art.By using phosphine such as triphenylphosphine and azo-group dicarboxylate derivatives such as azo-group dicarboxylate at aprotic solvent such as tetrahydrofuran (THF) or N, handle in the dinethylformamide, the hydroxy functional group of compound N is replaced with nucleophilic reagent such as compound M or its deprotonation derivative.The cyclization of compound O is preferably in the presence of palladium catalyst (for example palladium diacetate), under alkaline condition (for example, be determined on a case-by-case basis and be mixed with the alkali metal acetate of phase transfer reagent such as Tetrabutyl amonium bromide), at aprotic solvent such as acetonitrile or N, in the dinethylformamide, in temperature is to carry out (R.Grigg etc., " tetrahedron ", the 4003rd page (1990)) under 50 to 120 ℃.

The compound of formula M can prepare according to the following method of feature:

-general formula following, R wherein ₁And R ₂₀Definition as above and R ₂₄The carbonyl of the pyridine of expression halogen atom or lower alkoxy is protected with acetal functional group,

Thereby the compound of preparation general formula F

R wherein ₁, R ₂₀And R ₂₄Definition is as above and Z and Z ' group are represented low alkyl group independently or form 2 to 4 yuan stable hydrocarbon together:

Thereby-methylol functional group is introduced the compound of preparation general formula G in the compound of general formula F

R wherein ₁, R ₂₀, R ₂₄, Z and Z ' definition as above,

-protect the alcohol functional group of general formula G compound to prepare the compound of general formula H then

R wherein ₁, R ₂₀, R ₂₄, Z and Z ' definition as above and R ₂₅The protecting group of expression alcohol functional group.

-with the acetal deprotection of the compound of general formula H with the preparation general formula I ' compound

R wherein ₁, R ₂₀, R ₂₄And R ₂₅Define as above,

Thereby-with the functionalization alkylating reagent handle Compound I ' compound preparation general formula J

R wherein ₁, R ₂₀, R ₂₄And R ₂₅Define as above R ₁₇, R ₁₈And R ₁₉Define as general formula I I,

The protecting group R of-general formula J compound ₂₅Cracking is with the compound of preparation general formula K

R wherein ₁, R ₁₈, R ₁₉, R ₂₀And R ₂₄Define as above, and R ₁₇Expression OR ₆Or NHR ₆, R ₆Expression H, low alkyl group, cycloalkyl, low alkyl group cycloalkyl, low-grade alkenyl, low alkyl group lower alkoxy or aryl or low-grade alkylaryl,

-be the compound of general formula L with the cyclization of general formula K compound

R wherein ₁, R ₁₈, R ₁₉, R ₂₀And R ₂₄Define as above, and last

The R of-compound L ₂₄Group changes carbonyl into, obtains the compound of formula M

R wherein ₁, R ₁₈, R ₁₉And R ₂₀Definition as above.

4-acyl group-2-haloperidid is (for example according to Lammattina J.L. " heterocyclic chemistry magazine " 20, the 553rd page (1983) acquisition) carbonyl functional group is preferably by acetal functional group, the protection of preferred ring acetal, this protection is according to those skilled in the art's currently known methods (Greene.T., " protecting group of organic synthesis " 10-86 (John Wiley ﹠amp; Sons 1981)) carry out.At aprotic solvent (for example, acetonitrile) or prepare in the alcohol of this alcoholate, is 0 ℃ to 100 ℃ in temperature with the alcoholate of sodium or potassium, handles the as above intermediate of preparation, obtains the compound of general formula F.With its 3 by with aryl or lithium alkylide (for example, basic lithium) in ether solvents such as tetrahydrofuran (THF), handle lithiumation at-100 to 0 ℃.With formylation electrophilic reagent such as N, dinethylformamide joins in the lithiumation intermediate that so obtains, and after the hydrolysis, thereby the aldehyde that so obtains is handled the compound for preparing general formula G with reductive agent such as sodium borohydride.Carry out the protection of the alcohol functional group of compound G according to standard conditions well known by persons skilled in the art, thus the compound of preparation general formula H.The example of the protecting group of alcohol functional group comprises those groups of forming ether (be methyl, methoxymethyl, THP trtrahydropyranyl, 2-methoxy ethoxy methyl, benzyloxymethyl, the tertiary butyl and be substituted or unsubstituted benzyl), and those groups that form ester (manthanoate, acetic ester and isobutyrate).Other example of the protecting group of primary hydroxyl is referring to Greene.T., " protecting group of organic synthesis " 10-86 (John Wiley ﹠amp; Sons 1981).In order to prepare general formula I ' compound the process of general formula H compound deprotection is carried out under the selection condition of keeping R25 group integrity, for example, by (as using trifluoroacetic acid) processing under acidic conditions.The selected condition of the protection of functional group and deprotection is (Greene.T., " protecting group of organic synthesis " 10-86 (John Wiley ﹠amp well known by persons skilled in the art; Sons 1981)).Handling the reaction of the beta-hydroxy esters of Compound I ' preparation general formula J with the functionalization alkylating reagent can use the zinc derivative of enol lithium or carboxylicesters to carry out in anhydrous aprotic solvent such as tetrahydrofuran (THF).The protecting group R of general formula J compound ₂₅Thereby the compound of fracture preparation general formula K under deprotection condition well known by persons skilled in the art.For example, work as R ₂₅When being benzyl, with the alcoholic solution of general formula J compound with add wherein palladium catalyst to place pressure be the nitrogen atmosphere of 0.5 to 10 crust.The ring-closure reaction of the general formula K compound that so obtains can (for example carry out under acidic conditions, by with trifluoroacetic acid or be dissolved in anhydrous solvent such as methylene dichloride Huo diox in the spirit of salt gas processing) be prepared as the beta-hydroxy lactonic ring of 7 yuan of rings, for example compound of general formula L.The compound of general formula L can change the pyridone of formula M into, for example, and by handling with hot spirit of salt, or by handling with Iodotrimethylsilane.

2-halo-3-quinoline methanol of general formula N can be begun preparation by the monoacetylaniline of general formula P,

R wherein ₂, R ₃And R ₄Definition is described in general formula I and II compound.In the method below, if desired then can be according to standard guard method (Greene.T., " protecting group of organic synthesis " 10-86 (John Wiley ﹠amp; Sons 1981)) protection R ₂, R ₃And R ₄Group.

So can obtain the compound of formula N according to the methods below: by with acylating reagent as diacetyl oxide handle with as described in the aniline N-ethanoylization of formula P.With the N-ethanoyl aniline that so makes at 50 to 100 ℃, under preferred 75 ℃, (act on N at 0 to 10 ℃ with so-called Vilsmeyer reagent well known by persons skilled in the art by phosphinylidyne oxygen chlorine, dinethylformamide makes) thus processing (for example prepares corresponding 2-chloro-3-quinoline aldehyde, referring to Meth-Cohn etc., " chemistry meeting meeting will ", Perkin Trans.I, the 1520th page (1981); Meth-Cohn etc., " chemistry can will ", Perkin Trans.I, the 2509th page (1981) and Nakasimhan etc., " American Chemical Society's meeting will " 112, the 4431 pages (1990)).By in inert solvent such as acetonitrile in the presence of iodine or bromine salt (for example sodium iodide or Tetrabutyl amonium bromide) with product heating, the chlorine on 2 of the 2-chloro-3-quinoline aldehydes can be replaced by iodine or bromine.May need the acid such as the concentrated hydrochloric acid of trace to come this conversion process of catalysis.This 2-halo-3-quinoline aldehyde is easy to be reduced to 2-halo-3-quinoline methanol of corresponding general formula N, this method is carried out under those skilled in the art's known standard condition, for example is 0 to 40 ℃ with sodium borohydride in temperature in alcoholic solvent (for example methyl alcohol) and handles down.

The compound of formula N also can prepare according to the methods below: the aniline of definition general formula P as above by with nitrile (as chloro acetonitrile or propionitrile) in the presence of boron trichloride and another Lewis acid such as aluminum chloride, titanium tetrachloride or diethyl aluminum chloride; in the mixture of aprotic solvent or aprotic solvent, react; hydrolysis then is (referring to Sugasawa T. etc.; " American Chemical Society can will " 100, the 4842 pages (1978)) and by acidylate.In aprotic solvent such as acetonitrile, in the presence of alkali such as triethylamine, handle the intermediate that as above makes with the ethyl malonyl chloride then, handle in methyl alcohol with alkali metal alcoholate such as sodium methylate then, thereby prepare the 2-hydroxyl-3-quinoline ethyl formate of 4 replacements.Change it into 2-chloro-3-quinoline ethyl formate by handling with phosphinylidyne oxygen chlorine.When 4 bit strips of quinoline have chloromethyl, can carry out nucleophilic substitution by handling with secondary amine such as dimethyl amine, N methyl piperazine, morpholine or piperidines.In aprotic solvent such as methylene dichloride, the reduction of this 2-chloro-3-quinoline ethyl formate is obtained the 2-chloro-3-quinoline methanol of general formula N then with diisobutyl aluminium hydride.The analogue of midbody compound (N) has been described in the document, particularly in the PCT application 95/05427.

Some compound of the present invention can be prepared as the form of pharmaceutical salts according to ordinary method.For example, acceptable salt includes but not limited to and mineral acid example hydrochloric acid, sulfuric acid, phosphoric acid, bisphosphate, Hydrogen bromide and nitric acid or organic acid such as acetate, toxilic acid, fumaric acid, tartrate, succsinic acid, citric acid, lactic acid, methylsulfonic acid, tosic acid, 1, the additive salt that 1 '-methylene radical-two (2-hydroxyl-3-naphthoic acid), Whitfield's ointment, oxalic acid and stearic acid form.When they can utilize, the salt that forms with alkali such as sodium hydroxide or potassium hydroxide also was a part of the present invention.Other example of pharmaceutical salts sees also " pharmaceutical salts ", " pharmacology magazine " 66:1 (1977).

Compound of the present invention has useful pharmaceutical properties.Therefore compound of the present invention is inhibited and have an anti-tumor activity to topoisomerase I and/or II.Prior art hints that compound of the present invention has parasiticide and/or antiviral activity.Compound of the present invention thereby can be used to during different treatment uses.

Experimental section hereinafter, for example pharmaceutical properties of clear The compounds of this invention.

By use the formula (I) or (II) compound of treatment significant quantity to the patient, this compound can suppress patient for example Mammals such as the intravital topoisomerase of people, for example I and/or II type.

Compound of the present invention also has anti-tumor activity.By use the formula (I) or (II) compound of treatment significant quantity to the patient, they can be used for treating tumour, for example express the tumour of topoisomerase.The example of tumour or cancer comprises the cancer that esophagus, stomach, intestines, rectum, oral cavity, pharynx, larynx, lung, colon, mammary gland, uterus, uterine endometrium, ovary, prostate gland, testis, bladder, kidney, liver, pancreas, bone, reticular tissue, skin, eye, brain and central nervous system position take place, and thyroid carcinoma, leukemia, Hokdkin disease, except the lymphoma relevant, multiple myeloma etc. with Hokdkin disease.

Suppress plasmodium (as in malaria) by suppressing hemoflagellate (for example in trypanosome or infections of Leishmania) or passing through, they can be used for treating parasitic infection, also can treat virus infection and disease.

These character make formula (I) or product (II) be suitable for medicinal application.Theme of the present invention also has as the above-mentioned formula (I) of medicine or product (II) and described formula (I) or (II) additive salt of product and medicinal inorganic or organic acid formation, and contains the pharmaceutical composition of at least a qualification medicine as above as activeconstituents.

Therefore, the present invention relates to contain and the pharmaceutical carrier blended of selecting according to medication (for example oral, intravenously, intraperitoneal, intramuscular, transdermal or subcutaneous), The compounds of this invention or its pharmaceutical composition with the additive salt of medicinal acid formation.This pharmaceutical composition (for example treatment) can be solid, liquid, liposome or lipid micella.

This pharmaceutical composition can be a solid form, for example, and powder, pill, granule, tablet, liposome, gelatine capsule or suppository.This pill, tablet or gelatine capsule can be with certain material dressings, and this material can protect this composition not to be subjected to the effect of hydrochloric acid in gastric juice or enzyme under one's belt in time enough, makes said composition enter small intestine with the form that is not digested.This compound also can local use, for example at the site of pathological change of tumour.This compound also can be according to the method administration (for example slow releasing composition or infusion pump) of slowly-releasing.Suitable solid carrier for example, can be calcium phosphate, Magnesium Stearate, magnesiumcarbonate, talcum, sugar, lactose, dextrin, starch, gelatin, Mierocrystalline cellulose, methylcellulose gum, Xylo-Mucine, polyvinylpyrrolidone and wax.This pharmaceutical composition that contains The compounds of this invention can also be a liquid form, for example, and solution, emulsion, suspension or sustained release preparation.The appropriate liquid carrier can be, for example, and water, organic solvent such as glycerine or glycol such as polyoxyethylene glycol, and the mixture that forms in varing proportions of they and water.

Theme of the present invention also comprises definition formula (I) or the purposes of product (II) aspect the following medicine of preparation as above: the medicine that suppresses topoisomerase and particularly I or II type topoisomerase, the medicine of treatment tumour, the medicine of treatment parasitic infection and treatment medicine for treating viral infections.

The dosage that is used for the treatment of the The compounds of this invention of above-mentioned disease or disorder, according to medication, patient's age and body weight and patient's body changed condition, and at last by curing mainly doctor or animal doctor decision.By curing mainly the doctor or the amount determined of animal doctor is referred to herein as " treatment significant quantity ".

Unless otherwise limit, all scientific and technical terminologies are identical with the implication of one skilled in the art's common sense of the present invention herein.All publications of mentioning equally, herein, patent application, all patents and all other reference are incorporated herein by reference.

The following example is used for illustrating aforesaid method, and can be counted as limitation of the scope of the invention in no instance.

Experimental section

Preparation example 1:5-ethyl-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

1.a. 4-ethyl-3,4-dihydroxyl-1H-pyrans also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-14 (4H, 12H)-ketone

With sodium borohydride (14g, 370mmol) join (S)-(+)-camptothecine (14g in batches, 40mmol, can be available from different places such as Aldrich Chemical Co. (Milwaukee, WI)) in the suspension in methyl alcohol (750ml), thereby and the gained mixture leniently be heated to 55 ℃ obtain transparent solution, again with this solution stirring at room 16 hours.Then, reduction vaporization falls solvent, reclaims this resistates in water (250ml), adds acetate (21ml) neutralization, and places 2 hours at 4 ℃.Also with cold water, acetone and ether continuous washing, the product that obtains forms white solid purpose compound, m.p.280 ℃ behind drying under reduced pressure with the gained suspension filtered.

1.b. 8-formyl radical oxygen ylmethyl-7-propionyl indolizino [1,2-b] quinoline-9 (11H)-ketone

With sodium metaperiodate (14g, water 65mmol) (140ml) drips of solution is added to 4-ethyl-4,5-dihydroxyl-1H-pyrans also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-14 (4H, 12H)-ketone (13.4g, in Glacial acetic acid 38mmol) (720ml) suspension, and with gained solution stirring at room 1 hour.Then, this reaction mixture is poured in ice/water mixture (650ml), and again gained suspension is stirred half an hour, filter then and water, Virahol and ether continuous washing, behind the drying under reduced pressure, obtain product (11.5g), its form is a faint yellow solid, m.p.＞200 ℃ (decomposition).

1.c. β-ethyl-beta-hydroxy-β-(8-hydroxymethyl-9-oxo (11H)-indolizino [1,2-b] quinoline-7-yl) propionic acid tertiary butyl ester

Will (6.5g, suspension 100mmol) be by dripping chloro trimethyl silane (0.75ml, 5.7mmol) activation with the zinc of magnetic stirrer under argon atmospher at anhydrous diethyl ether (50ml).Room temperature continue to stir 15 minutes and with this reaction medium reflux.(15ml, 100mmol), rate of addition is guaranteed to continue to reflux for tert.-butyl acetate to remove heating bath and dripping bromine.Be placed in the external heat source again and continue and heated 1 hour.To place by the ethereal solution that Reformatsky reagent obtains and be cooled to room temperature; under argon atmospher, it is transferred to 8-formyl radical oxygen ylmethyl-7-propionyl indolizino [1 then with conduit; 2-b] (1.6g is in anhydrous tetrahydro furan 4.7mmol) (40ml) suspension for quinoline-9 (11H)-ketone.To stir 1 hour under this reaction mixture refluxed, also also (3 * 100ml) extract with chloroform by adding saturated ammonium chloride (100ml) stopped reaction to be cooled to room temperature then.With the chloroform extract that dried over sodium sulfate merges, evaporation and on silicagel column (1-2% ethanol/methylene) carry out chromatogram purification, obtain 0.64g product (31%), its form is a faint yellow solid, m.p.146-149 ℃.NMR-1H(CDCl ₃)：0.93(t，3H)；1.37(s，9H)；1.99(m，2H)；2.97(dd，2H)；3.5(se，1H)；5.10(s，2H)；5.24(s，2H)；7.40(s，1H)；7.59(t，1H)；7.83(t，1H)；7.90(d，1H)；8.20(d，1H)；8.34(s，1H).NMR-C13(CDCl ₃)：8.18；27.90；34.59；45.34；49.91；58.55；77.39；82.42；100.52；127.67；127.97；128.10；128.64；129.44；129.79；130.42；130.99；142.86；148.69；152.75；155.16；162.38；172.24.IR(KBr)：764；1016；1157；1580；1651；1726.

1.d. 5-ethyl-4,5-dihydro-5-hydroxyl-lH-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

With β-ethyl-beta-hydroxy-β-(8-hydroxymethyl-9-oxo (11H)-indolizino [1,2-b] quinoline-7-yl) (1.45g 3.32mmol) is dissolved in the saturated dichloromethane solution (100ml) of also using hydrogenchloride in the anhydrous methylene chloride (25ml) and handles the propionic acid tertiary butyl ester.The gained mixture was kept 16 hours at-20 ℃.Leach precipitation, with methanol wash and drying under reduced pressure, obtain 662mg (55%) title compound, its form is a yellow solid, m.p.＞300 ℃.NMR-1H(DMSO)：0.90(t，3H)；1.20(q，2H)；3.27(dd，2H)；5.29(s，2H)；5.49(dd，2H)；7.42(s，1H)；7.73(t，1H)；7.90(t，1H)；8.16(t，2H)；8.71(s，1H).NMR-C13(DMSO)：8.45；36.48；42.54；50.68；61.44；73.34；99.78；122.71；127.83；128.15；128.75；129.08；130.07；130.61；131.81；144.66；148.04；152.80；155.91；159.26；172.08.IR(KBr)：761；1127；1204；1285；1580；1653；1757.

Preparation example 2:5-ethyl-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-fractionation of diketone

With β-ethyl-beta-hydroxy-β-(8-hydroxymethyl indolizino [1,2-b] quinoline-9-(11H)-ketone-7-yl) propionic acid (19.5g, 51mmol) and L-(-)-α-Jia Jibianji amine (12.12g, 100mmol) mixture heating up in straight alcohol (1l) is filtered in the time of heating and it was placed 68 hours to boiling.Leach precipitation and obtain the 9.8g white solid with ethanol and ether washing.By high pressure liquid chromatography on chiral stationary phase (at Chiral-AGP post (Chromtech, Stockholm, Sweden) carry out " chirality HPLC " 100 * 4mm on, elutriant is the 10mM phosphoric acid buffer pH6.9 of 2% acetonitrile, elution peak appearred at 4.5 and 7.5 minutes) analyze two peaks, and its integral area accounts for 24% and 76% of two peak total areas respectively.This solid is refluxed in 93% ethanol (350ml), placed then 48 hours.Leach this precipitation, obtain the 4.8g white solid with ethanol and ether washing then, analyze with chirality HPLC and produce two peaks, account for 9% and 91% of two peak total areas respectively.Also placed again 48 hours with 50% ethanol (48ml) backflow.Leach precipitation and obtain the 2.7g white solid, analyze with chirality HPLC and produce two peaks, account for 3% and 97% of two peak total areas respectively with ethanol and ether washing.This solid is refluxed in 50% ethanol (22ml), placed then 48 hours.Leach this precipitation and obtain the 1.6g white solid with ethanol and ether washing again, analyze with chirality HPLC and produce two peaks, account for 1% and 99% of two peak total areas respectively.The gained salt of enrichment diastereomer is dissolved in the distilled water (20ml), and (0.35ml 6.4mmol) handled 15 minutes with acetate.Leach the gained precipitation, water, acetone and ether washing obtain the 1.1g white solid 80 ℃ of vacuum-dryings then.Be dissolved in it in straight alcohol (55ml) and add concentrated hydrochloric acid (11.5N 11ml) obtains yellow solution, with it stirring at room 68 hours.Leach gained precipitation and water, ethanol and ether washing, obtain the 5-ethyl-4 of 770mg enrichment enantiomer then 80 ℃ of vacuum-dryings, 5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone.By chirality HPLC (the Chiral-AGP post carried out gradient elution with the 10mM phosphoric acid buffer pH6.9 that contains 2 to 5% acetonitriles, elution peak occurred at 15 minutes and 20 minutes) analysis revealed enantiomeric excess 98%.Substitute L-(-)-α-Jia Jibianji amine with D-(+)-α-Jia Jibianji amine and carry out aforesaid method again.So just, obtain 5-ethyl-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-another enantiomorph of diketone.

Preparation example 3:5,12-diethyl-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

Removing step 1.a. replaces preparing this compound according to the method that is similar to preparation example 1 outside the camptothecine with 7-ethyl-camptothecin (Sawada etc., " pharmaceutical chemistry circular " 39:2574 (1991)).The title compound that obtains is the aureus solid, m.p.＞270 ℃.NMR-1H(DMSO)：0.92(t，3H)；1.39(t，3H)；1.93(q，2H)；3.08(d，2H)；3.25(q，2H)；3.51(d，2H)；5.32(s，2H)；5.52(dd，2H)；7.42(s，1H)；7.76(t，1H)；7.89(t，1H)；8.18(d，1H)；8.32(d，1H).NMR-C13(DMSO)：8.46；14.15；22.42；36.50；42.54；49.95；61.45；73.35；99.68；122.61；124.27；126.76；127.70；128.27；129.92；130.18；145.17；145.82；148.57；152.15；155.89；159.26；172.08.

Preparation example 4:5-ethyl-9,10-two fluoro-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

4.a. 2-ethyl-2-(2-methoxyl group-4-pyridyl)-1, the 3-dioxolane

With Dean Stark instrument from deriving from Lamattina; J.L. " heterocyclic chemistry magazine " 20; the 2-chloro-4-propionyl pyridine of the 553rd page (1983) (10g, 59mmol), steam water (spending the night) in the azeotropic mode in ethylene glycol (20ml) and the mixture of tosic acid (250mg) in toluene (150ml).Removal of solvent under reduced pressure neutralizes this acid also with this product of extracted with diethyl ether with saturated sodium bicarbonate aqueous solution (100ml) then.Ether extract with salt water washing merging; with dried over sodium sulfate and evaporation; obtain 13.3g (96%) by the crude product of carbonyl-protection; with itself and 3 normal sodium methylates in acetonitrile reflux to reaction thoroughly (pass through thin-layer chromatography: silicon-dioxide, t-butyl methyl ether/hexane (TBMO/HX) 50/50 detects).Filter this acetonitrile solution and evaporation then.This resistates of dissolving in ether, water and salt water washing with dried over sodium sulfate and evaporation, obtain brown oil, with its distillation (70-75 ℃, 0.04 millibar); Obtain 10.7g (total recovery 81%) product (F), be transparent oily matter.

4.b. 2-ethyl-2-(3-methylol-2-methoxyl group-4-pyridyl)-1, the 3-dioxolane

Under-78 ℃ of argon atmosphers, ((13ml is in anhydrous tetrahydro furan 85mmol) (300ml) solution 170mmol) to be added drop-wise to bromo for 1.7M pentane solution, 100ml with tert-butyl lithium with conduit.The gained white precipitate was stirred 1 hour at-78 ℃, add 2-ethyl-2-(2-methoxyl group-4-pyridyl)-1 then, and the 3-dioxolane (10g, 44.8mmol), again this reaction mixture was stirred 15 minutes at-78 ℃, stirred 1 hour and stirring at room 1 hour at 0 ℃.It is cooled to-78 ℃ again, adds anhydrous N, dinethylformamide (100mmol) is heated this reaction mixture to room temperature and was stirred 16 hours, and (silicon-dioxide, TBMO/HX:50/50) the explanation initiator thoroughly reacts by thin-layer chromatographic analysis afterwards.(200ml, 50ml 50ml) extract this reaction mixture with the saturated ammonium chloride stopped reaction and with ether.Extract and evaporation with dried over sodium sulfate merges obtain yellow oil, obtain intermediate aldehydes (7g) by column chromatography (silicon-dioxide, this derivative of TBMO/HX:0/100 to 5/95 wash-out are used 20/80 to 50/50 this product of wash-out then) purifying.This aldehyde is dissolved in methyl alcohol (100ml) and (5g 132mmol) handles, and the gained mixture is stirred to by the thin-layer chromatography control analysis illustrates that this intermediate aldehydes thoroughly reacts (about 1 hour) with sodium borohydride.Solvent evaporated then, and in ether this resistates of dissolving, water and salt water washing, dry and solvent evaporated.This resistates is carried out column chromatography (silicon-dioxide, TBMO/HX:10/90 to 50/50) purifying obtain 7g (total recovery 62%) product (G), be yellow oil.

4.c. 2-(3-benzyloxymethyl-2-methoxyl group-4-pyridyl)-2-ethyl-1, the 3-dioxolane

With 2-ethyl-2-(3-methylol-2-methoxyl group-4-pyridine)-1,3-dioxolane (7g, 30mmol) and benzyl chloride (5ml, anhydrous tetrahydro furan 45mol) (50ml) solution, (80% in mineral oil to be added drop-wise to sodium hydride, 1.85g, in anhydrous tetrahydro furan 6lmmol) (100ml) suspension, and this reaction mixture kept 16 hours under reflux state.Then this reaction mixture is cooled to room temperature, water (50ml) stopped reaction and this reaction mixture of concentrating under reduced pressure.Be dissolved in the ether (150ml) this resistates and water and salt water washing, dry and evaporation.Carry out purifying by column chromatography (silicon-dioxide, TBMO/HX:5/95 to 20/80) and obtain 9g (87%), be transparent oily matter by the product of benzyl protection (H).

4.d. 1-(3-benzyloxymethyl-2-methoxyl group-4-pyridyl)-propane-1-ketone

With 2-(3-benzyloxymethyl-2-methoxyl group-4-pyridyl)-2-ethyl-1, (9g 27mmol) handled 3 hours in the heating bath of 120 ℃ of temperature with trifluoroacetic acid (10ml) and water (5ml) the 3-dioxolane.With this reaction mixture concentrating under reduced pressure, by adding in the saturated sodium bicarbonate aqueous solution and the acid of remaining trace.Extract with ether, (silicon-dioxide, TBMO/HX:10/90) purifying obtains 5.5g (70%) product (I) by column chromatography then.

4.e. β-ethyl-beta-hydroxy-β-(3-benzyloxymethyl-2-methoxyl group-4-pyridyl)-propionic acid tert-butyl ester

(13ml 80mmol) is added drop-wise in anhydrous tetrahydro furan (60ml) suspension of the zinc (5.3g, 80mmol with 6N HCl activation 10 seconds, are washed with water to pH then successively for neutral, with acetone and ether washing) under the reflux state with the monobromo-acetic acid tert-butyl ester.After dropwising, this reaction medium is kept backflow 10 minutes again.Then, (5.8g, (20ml) solution of anhydrous tetrahydro furan 20mmol) also refluxes this reaction mixture again and to stir 1 hour to add 1-(3-benzyloxymethyl-2-methoxyl group-4-pyridyl)-propane-1-ketone.At 0 ℃ with saturated aqueous ammonium chloride (100ml) stopped reaction, and with this reaction mixture of extracted with diethyl ether.Extract and evaporation with dried over sodium sulfate merges obtain yellow oil, and it is obtained tertiary butyl ester (J) (7g, 95%) by column chromatography (silicon-dioxide, TBMO/HX:5/95 to 10/90) purifying, are transparent oily matter.

4.f. β-ethyl-beta-hydroxy-β-(3-hydroxymethyl-2-methoxyl group-4-pyridyl)-propionic acid tert-butyl ester

(1g 2.5mmol) makes catalyzer (50mg) with 5% palladium/carbon and makes solvent (10ml) with straight alcohol and carry out hydrogenolysis under normal pressure and room temperature with β-ethyl-beta-hydroxy-β-(3-benzyloxymethyl-2-methoxyl group-4-pyridyl)-propionic acid tert-butyl ester.Reaction obtains 0.7g (90%) product (K) in case termination (6 hours) just leaches catalyzer and solvent evaporated, and its purity is enough to be used in subsequent reaction.

4.g. 5-ethyl-1,5-dihydro-5-hydroxyl-9-methoxyl group-oxepin is [3,4-c] pyridines-3 (4H)-ketone also

(8.8g 28mmol) uses trifluoroacetic acid (30ml) room temperature treatment 3 hours with β-ethyl-beta-hydroxy-β-(3-hydroxymethyl-2-methoxyl group-4-pyridyl)-propionic acid tert-butyl ester.Evaporate volatile component and this resistates is passed through column chromatography (silicon-dioxide, methylene chloride: 100/0 to 98/2) carry out purifying, obtain transparent oily matter, after O for toluene, obtain 5.9g (89%) product (L), be white crystals, m.p.97-98 ℃.

4.h. 5-ethyl-1,5-dihydro-5-hydroxyl-oxepin also [3,4-c] pyridine-3,9 (4H, 8H)-diketone

With 5-ethyl-1,5-dihydro-5-hydroxyl-9-methoxyl group-oxepin is [3,4-c] pyridines-3 (4H)-ketone (0.5g, 2.1mmol) reflux 9 hours in 1N hydrochloric acid (20ml) also.With this reaction mixture concentrating under reduced pressure and by adding and evaporating toluene, in the presence of Vanadium Pentoxide in FLAKES, reduce pressure then its placement is spent the night this resistates drying.Gained oily matter is dissolved in the anhydrous acetonitrile (5ml), and under argon atmospher, stirred 24 hours.Leach precipitation and dry, obtain 0.23g (49%) white solid (M), m.p.118-119 ℃.

4.i. 2-chloro-6,7-two fluoro-3-quinoline-methyl alcohol

Use Meth-Cohn and colleague thereof at the 1520th page of J.Chem.Soc.Perkin Trans.I. (1981); Meth-Cohn is in the method for the 2509th page of (1981) description of J.Chem.Soc.Perkin Trans.I..With 3; (38g 22mmol) joins by (34ml drips phosphoryl chloride oxygen (103ml in 44mmol) to anhydrous dimethyl formamide 4-two fluoro-N-ethanoyl aniline; 1.1mmol) in the Vilsmeyer reagent of preparation, the cooling of water/ice bath was also stirred 0.5 hour under argon atmospher.The gained mixture was heated 16 hours at 70 ℃.After being cooled to room temperature, this reaction mixture is joined in the mixture of ice and water (400ml), and continue to stir 2 hours, filtration and water, ethanol and ether continuous washing prepare 9g 2-chloro-6 then, 7-difluoro-quinoline-3-formaldehyde is yellow solid, m.p.222-224 ℃.With sodium borohydride (2g, 52mmol) in methyl alcohol (400ml) in this intermediate of room temperature treatment 0.5 hour, destroy excessive reagent by adding acetate (2ml) then.This solvent is removed in decompression, this resistates is joined in the ethyl acetate solution also wash successively with rare sodium bicarbonate, water and saturated sodium-chloride water solution.Use dried over sodium sulfate, filter and concentrated organic phase.With 1, the 2-ethylene dichloride obtains 8g 2-chloro-6 with gained solid recrystallization, and 7-two fluoro-3-quinoline-methyl alcohol are the beige solid.

4.j. 5-ethyl-8-(2-chloro-6,7-two fluoro-3-quinoline methyl)-1,5-dihydro-5-hydroxyl-oxepin also [3,4-c] pyridine-3,9 (4H, 8H)-diketone

With azo-group dicarboxylate (570 μ l, 3.6mmol) in 5 minutes, be added drop-wise to 5-ethyl-1,5-dihydro-5-hydroxyl-oxepin is [3,4-c] pyridine-3,9 (4H also, 8H)-diketone (400mg, 1.79mmol), the compound that obtains of step 4.i. (770mg, 2.23mmol) and triphenylphosphine (934mg, anhydrous N 3.58mmol), in dinethylformamide (45ml) solution, and the gained mixture stirred 16 hours under argon atmospher in room temperature.This reaction mixture of concentrating under reduced pressure and this resistates is dissolved in the ether (100ml) then.(4 * 50ml) washing gained solution are with dried over sodium sulfate and evaporation with salt solution.This resistates is passed through column chromatography (silicon-dioxide, methylene chloride: 99/1 to 98/2) carry out chromatogram purification, obtain 650mg (66%) product (O), be white solid, m.p.165-167 ℃.

4.k. 5-ethyl-9,10-two fluoro-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

With 5-ethyl-8-(2-chloro-6,7-two fluoro-3-quinoline methyl)-1,5-dihydro-5-hydroxyl-oxepin also [3,4-c] and pyridine-3,9 (4H, 8H)-diketone (600mg, 1.1mmol), Tetrabutyl amonium bromide (352mg, 1.1mmol), sodium-acetate (359mg, 4.4mmol) and palladium II (98mg 0.43mmol) is dissolved in the anhydrous acetonitrile (40ml) and 90 ℃ of heating 16 hours under argon atmospher.After being cooled to room temperature, from red solution, isolate white precipitate.Leach this precipitation and drying under reduced pressure.This crude product is suspended in water, filter also and use the Vanadium Pentoxide in FLAKES drying under reduced pressure, obtain the 250mg title compound, be beige solid, m.p.＞250 ℃.NMR-1H(DMSO)：0.91(t，3H)；1.87(m，2H)；3.08(d，1H)；3.51(d，1H)；4.45(s，4H)；5.19(s，2H)；5.47(dd，2H)；6.02(se，1H)；7.33(s，1H)；7.54(s，1H)；7.55(s，1H)；8.43(s，1H).NMR-C13(DMSO)：8.43；36.47；42.54；50.52；61.43；64.43(2C)；73.31；99.07；112.27；113.14；122.00；124.24；128.18；129.74；144.59；145.01；145.33；147.63；150.88；155.88；159.23；172.07.

Preparation example 5:5-ethyl-4,5-dihydro-5,10-dihydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

Making catalyzer (60mg) and trifluoroacetic acid with 10% palladium/carbon with hydrogen under normal pressure and room temperature makes solvent (15ml) and handles 10-benzyloxy-5-ethyl-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone (370mg, 0.79mmol).In case reaction stops (16 hours), just adds methylene dichloride (50ml) and methyl alcohol (50ml) in this reaction mixture, leaches catalyzer and reduction vaporization volatiles, obtains containing the title crude product of trace trifluoroacetic acid like this.By with 1,4-diox condistillation is removed the trifluoroacetic acid of trace.Obtain the orange solid product, m.p.150 ℃ (decomposition), its purity is enough to be used in subsequently synthetic.NMR-1H(DMSO)：0.89(t，3H)；1.85(q，2H)；3.02(d，1H)；3.45(d，1H)；5.19(s，2H)；5.37(d，1H)；5.50(d，1H)；5.98(se，1H)；7.26(s?1H)；7.31(s，1H)；7.40(d，1H)；8.00(d，1H)；8.42(s，1H)；10.32(s，1H).NMR-C13(DMSO)：8.47；36.50；42.61；50.57；61.46；73.35；98.84；109.02；121.83；123.18；129.50；129.85；130.12；130.80；143.39；145.10；149.69；155.97；156.82；159.30；172.11.

Preparation example 6:5-ethyl-9-fluoro-4,5-dihydro-5-hydroxyl-10-methoxyl group-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, begin reaction by 3-fluoro-4-anisidine and obtain this compound, be yellow solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.89 (t, 3H); 1.85 (q, 2H); 3.08 (d, 1H); 3.49 (d, 1H); 4.00 (s, 3H); 5.25 (s, 2H); 5.39 (d, 1H); 5.51 (d, 1H); 6.00 (s, 1H); 7.32 (s, 1H); 7.72 (d, 1H); 7.91 (d, 1H); 8.58 (s, 1H) .NMR-C13 (DMSO): 8.43; 36.48; 42.51; 50.68; 56.60; 61.42; 73.29; 99.25; 108.68; 113.52; 122.23; 126.33; 129.99; 130.30; 143.79; 144.70; 148.42; 151.18; 153.19; 155.81; 159.20; 172.06.IR (KBr): 1259; 1503; 1602; 1737.

Preparation example 7:9-chloro-5-ethyl-4,5-dihydro-5-hydroxyl-10-methyl isophthalic acid H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, begin reaction by 3-chloro-4-anisidine and obtain this compound, be yellow solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 2.55 (s, 3H); 3.07 (d, 1H); 3.45 (d, 1H); 5.25 (s, 2H); 5.39 (d, 1H); 5.51 (d, 1H); 6.05 (s, 1H); 7.39 (s, 1H); 8.10 (s, 1H); 8.20 (s, 1H); 8.60 (s, 1H) .NMR-C13 (DMSO): 8.43; 20.20; 36.47; 42.49; 50.67; 61.41; 73.28; 99.87; 122.82; 126.98; 127.99; 129.60; 130.53; 131.08; 135.64; 136.56; 144.39; 147.11; 153.10; 155.85; 159.18; 172.03.IR (KBr): 1208; 1479; 1606; 1656; 1724.

Preparation example 8:8-ethyl-2,3,8,9-tetrahydrochysene-8-hydroxyl-10H, 12H-[1,4] two oxines also (dioxino) [2,3-g] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, by 3,4-ethylidene dioxy base aniline begins reaction and obtains this compound, is yellow solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 3.07 (d, 1H); 3.47 (d, 1H); 5.25 (s, 2H); 5.39 (d, 1H); 5.51 (d, 1H); 6.05 (s, 1H); 7.39 (s, 1H); 8.15 (q, 1H); 8.25 (q, 1H); 8.68 (s, 1H) .NMR-C13 (DMSO): 8.41; 36.45; 42.48; 50.68; 61.40; 73.25; 99.92; 114.44; 115.42; 115.58; 122.96; 125.52; 130.56; 131.46; 144.21; 145.25; 142.36; 153.41; 155.85; 159.15; 172.00.IR (KBr): 1266; 1512; 1581; 1618; 1751.

Preparation example 9:7-ethyl-7,8-dihydro-7-hydroxyl-9H, 11H-[1,3] dioxole also [4,5-g] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-9,12 (14H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, by 3,4-methylenedioxyphenyl amine begins reaction and obtains this compound, is white shape solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 3.07 (d, 1H); 3.45 (d, 1H); 5.20 (s, 2H); 5.39 (d, 1H); 5.51 (d, 1H); 6.00 (s, 1H); 6.30 (s, 2H); 7.30 (s, 1H); 7.49 (d, 2H); 8.45 (s, 1H) .NMR-C13 (DMSO): 8.43; 36.49; 42.56; 50.58; 61.42; 73.31; 98.87; 102.75; 103.33; 104.92; 121.76; 125.74; 128.59; 130.33; 145.08; 146.69; 148.78; 150.19; 151.49; 155.90; 159.24; 172.08.IR (KBr): 1248; 1459; 1606; 1731.

Preparation example 10:9-chloro-5-ethyl-4,5-dihydro-5-hydroxyl-10-methoxyl group-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, begin reaction by 3-chloro-4-anisidine and obtain this compound, be white solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 3.07 (d, 1H); 3.45 (d, 1H); 4.01 (s, 3H); 5.22 (s, 2H); 5.39 (d, 1H); 5.51 (d, 1H); 6.02 (s, 1H); 7.31 (s, 1H); 7.68 (s, 1H); 8.20 (s, 1H); 8.55 (s, 1H) .NMR-C13 (DMSO): 8.22; 36.27; 42.30; 50.48; 56.69; 61.23; 73.08; 99.16; 107.44; 122.16; 127.12; 128.12; 129.25; 130.02; 130.53; 143.29; 144.37; 151.12; 153.29; 155.71; 158.98; 171.84.IR (KBr): 1056; 1256; 1483; 1592; 1657; 1747.

Preparation example 11:5-ethyl-4,5-dihydro-5-hydroxyl-10-methoxyl group-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, begin reaction by the 4-anisidine and obtain this compound, be yellow solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 3.07 (d, 1H); 3.45 (d, 1H); 3.95 (s, 3H); 5.28 (s, 2H); 5.40 (d, 1H); 5.51 (d, 1H); 6.00 (s, 1H); 7.38 (s, 1H); 7.51 (d, 2H); 8.07 (d, 1H); 8.55 (s, 1H) .NMR-C13 (DMSO): 8.45; 36.48; 42.51; 50.64; 55.92; 61.42; 73.33; 99.01; 106.49; 122.02; 123.19; 129.59; 130.20; 130.43; 144.17; 144.94; 150.40; 155.92; 158.31; 159.26; 172.07.IR (KBr): 1251; 1604; 1655; 1735.

Preparation example 12:9,11-two chloro-5-ethyls-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, by 3, the 5-dichlorphenamide bulk powder begins reaction and obtains this compound, is yellow solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 3.07 (d, 1H); 3.45 (d, 1H); 5.30 (s, 2H); 5.41 (d, 1H); 5.55 (d, 1H); 6.08 (s, 1H); 7.41 (s, 1H); 8.05 (s, 1H); 8.21 (s, 1H); 8.91 (s, 1H) .NMR-C13 (DMSO): 8.39; 36.45; 42.51; 51.03; 61.39; 73.25; 100.62; 123.55; 124.63; 127.60; 128.08; 128.56; 132.06; 132.19; 134.53; 143.77; 148.80; 154.88; 155.82; 159.13; 171.98.IR (KBr): 1064; 1275; 1586; 1651; 1743.

Preparation example 13:5-ethyl-9-fluoro-4,5-dihydro-5-hydroxyl-10-methyl isophthalic acid H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, begin reaction by 3-fluoro-4-monomethylaniline and obtain this compound, be yellow solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.89 (t, 3H); 1.85 (q, 2H); 2.49 (s, 3H); 3.08 (d, 1H); 3.49 (d, 1H); 5.21 (s, 2H); 5.39 (d, 1H); 5.51 (d, 1H); 6.05 (s, 1H); 7.39 (s, 1H); 7.87 (d, 1H); 8.05 (d, 1H); 8.61 (s, 1H) .NMR-C13 (DMSO): 8.40; 15.14; 36.45; 42.52; 50.60; 61.41; 73.28; 99.71; 112.00; 122.66; 125.38; 127.66; 129.59; 130.28; 144.49; 147.88; 152.88; 155.85; 159.18; 162.25; 172.02.IR (KBr): 1054; 1580; 1651; 1760.

Preparation example 14:5-ethyl-10-fluoro-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, begin reaction by the 4-fluoroaniline and obtain this compound, be white solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 3.07 (d, 1H); 3.45 (d, 1H); 5.29 (s, 2H); 5.39 (d, 1H); 5.55 (d, 1H); 6.30 (s, 1H); 7.39 (s, 1H); 7.80 (q, 1H); 7.99 (q, 1H); 8.23 (q, 1H); 8.68 (s, 1H) .NMR-C13 (DMSO): 8.40; 36.46; 42.48; 50.66; 61.41; 73.31; 99.68; 111.83; 122.75; 128.93; 130.93; 131.22; 131.93; 144.46; 145.27; 152.60; 155.89; 159.21; 172.04.IR (KBr): 1209; 1589; 1659; 1739.

Preparation example 15:10-chloro-5-ethyl-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, begin reaction by the 4-chloroaniline and obtain this compound, be yellow solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 3.07 (d, 1H); 3.47 (d, 1H); 5.25 (s, 2H); 5.39 (d, 1H); 5.51 (d, 1H); 6.05 (s, 1H); 7.39 (s, 1H); 7.89 (d, 1H); 8.19 (d, 1H); 8.29 (s, 1H); 8.67 (s, 1H) .NMR-C13 (DMSO): 8.40; 36.46; 42.47; 50.70; 61.42; 73.31; 100.00; 122.96; 127.31; 127.42; 128.87; 131.11; 132.12; 144.34; 146.53; 153.38; 155.88; 159.20; 172.04.IR (KBr): 1069; 1483; 1606; 1741.

Preparation example 16:9-chloro-5-ethyl-10-fluoro-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

According to the method for preparation example 4 step 4i, 4j and 4k, begin reaction by 4-chloro-3-fluoroaniline and obtain this compound, be yellow solid, m.p.＞250 ℃ .NMR-1H (DMSO): 0.85 (t, 3H); 1.85 (q, 2H); 3.07 (d, 1H); 3.45 (d, 1H); 5.25 (s, 2H); 5.39 (d, 1H); 5.51 (d, 1H); 6.05 (s, 1H); 7.40 (s, 1H); 8.20 (d, 1H); 8.40 (d, 1H); 8.68 (s, 1H) .NMR-C13 (DMSO): 8.38; 36.47; 42.58; 50.71; 61.40; 73.26; 99.99; 113.59; 123.09; 124.28; 127.74; 130.64; 131.31; 144.13; 145.08; 153.57; 154.13; 155.84; 156.61; 159.14; 172.00.IR (KBr): 1488; 1583; 1655; 1743.

Preparation example 17:5,12-diethyl-9-fluoro-4,5-dihydro-5-hydroxyl-10-methoxyl group-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

17.a. 5-fluoro-4-methoxyl group-2-propionyl aniline

According to Sugasawa T, Toyoda T, Adachi M, Sasakura K, " American Chemical Society's meeting will ", and 100 (1978), the 4842-4852 page or leaf obtains this product.Under nitrogen atmosphere, at 0 ℃, to 3-fluoro-4-anisidine (20g, in anhydrous methylene chloride 142mmol) (200ml) solution, drip boron trichloride (1M in heptane, 156ml, 156mmol).The pink suspension that obtains was like this stirred 5 minutes, drip then propionitrile (33ml, 420mmol), again with short run add aluminum chloride (20.8g, 156mmol).With this reaction medium reflux 3 hours, be cooled to 0 ℃, add 2N hydrochloric acid (100ml) carefully and be hydrolyzed, reflux is 45 minutes then.After being cooled to 0 ℃, leach the gained precipitation, use washed with dichloromethane, in water (300ml), reclaim then.This water pH regulator to alkalescence, is used dichloromethane extraction, use ethyl acetate extraction again.Use the dried over mgso organic phase, evaporation obtains crude product then, and this crude product is passed through column chromatography (silicon-dioxide, ethyl acetate/heptane: 1/99 to 20/80) carry out purifying.Obtain the 15.3g yellow solid.NMR-1H(CDCl ₃)：1.20(t，3H)；2.92(q，2H)；3.83(s，3H)；6.2(s，2H)；6.40(d，2H)；7.32(d，2H).IR(KBr)：857；1148；1240；1561；1583；1662.

17.b. 4-ethyl-7-fluoro-2-hydroxyl-6-methoxyl group-3-quinoline ethyl formate

Under argon atmospher and 0 ℃; with ethyl malonyl chlorine (12.9ml; anhydrous acetonitrile 100mmol) (30ml) drips of solution be added to 5-fluoro-4-methoxyl group-2-propionyl aniline (15.3g, 77.5mmol) and triethylamine (13.9ml is in anhydrous acetonitrile 100mmol) (110ml) solution.Allow the temperature of this reaction medium get back to room temperature, under argon atmospher, drip alcohol sodium solution (by 1.8g, 78mmol sodium makes) by conduit in 80ml ethanol, room temperature stirs this reaction medium 12 hours then.Pour into this reaction mixture in the icy water (100ml) and stirred 2 hours, leach precipitation and water, ethanol and ether washing then.Obtain the 19.4g white solid.NMR-1H(DMSO)：1.25(m，6H)；2.78(q，2H)；3.92(s，3H)；4.30(q，2H)；7.15(d，2H)；7.40(d，2H)；11.93(s，1H).IR(KBr)：786；1083；1410；1521；1644；1725.

17.c. 2-chloro-4-ethyl-7-fluoro-6-methoxyl group-3-quinoline ethyl formate

With 4-ethyl-7-fluoro-2-hydroxyl-6-methoxyl group-3-quinoline ethyl formate (19.4g, phosphoryl chloride 0.066mol) (243ml) suspension reflux 6 hours.Distill phosphoryl chloride.This reaction mixture is poured in the icy water, then in methylene dichloride with its dissolving.Wash organic phase with water, wash with saturated nacl aqueous solution then.With the dried over mgso organic phase and with solvent evaporation.Be suspended in this resistates in the ether and leach unreacted initiator (4g).Pass through column chromatography (silicon-dioxide, ethyl acetate/heptane: 5/95 to 20/80) purifying with this filtrate evaporation and with this resistates.Obtain the 10.9g white solid.NMR-1H(DMSO)：1.30(t，3H)；1.39(t，3H)；3.08(q，2H)；4.09(s，3H)；4.49(q，2H)；7.64(d，2H)；7.86(d，2H).IR(KBr)：865；1016；1082；1190；1224；1253；1272；1508；1571；1732.

17.d. 2-chloro-4-ethyl-7-fluoro-6-methoxyl group-3-quinoline methanol

Room temperature, under inert atmosphere, (1M is in methylene dichloride with diisobutyl aluminium hydride, 65ml, (10.8g is in anhydrous methylene chloride 35mmol) (200ml) solution, then 40 ℃ of heating 4 hours 65mmol) to be added drop-wise to 2-chloro-4-ethyl-7-fluoro-6-methoxyl group-3-quinoline ethyl formate.After being cooled to 0 ℃, add 20% aqueous solution (105ml) and the methylene dichloride (200ml) of soluble tartrate sodium salt carefully, and this reaction mixture was stirred 1 hour, subsequently decant and washing with water 3 times.With the dried over mgso organic phase and with this solvent evaporation.This resistates is passed through column chromatography (silicon-dioxide, ethyl acetate/heptane: 5/95 to 50/50) purify.Obtain the 6g white solid.NMR-1H(DMSO)：1.28(t，3H)；3.25(q，2H)；4.04(s，3H)；4.77(d，2H)；5.27(t，1H)；7.55(d，2H)；7.73(d，2H).IR(KBr)：840；864；1023；1232；1267；1317；1444；1511；1569.

17.e. 5,12-diethyl-9-fluoro-4,5-dihydro-5-hydroxyl-10-methoxyl group-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

Described according to preparation example 4 step 4.j. with 2-chloro-4-ethyl-7-fluoro-6-methoxyl group-3-quinoline methanol and compound (M) coupling.The gained coupling product is according to the described method cyclization of step 4.k..Obtain yellow solid, m.p.＞275 ℃.NMR-1H(CF3COOD)：1.07(m，3H)；1.62(m，3H)；2.27(m，2H)；3.44(d，1H)；3.54(m，2H)；3.91(d，1H)；4.25(s，3H)；5.60(d，1H)；5.74(s，2H)；5.98(d，1H)；7.85(m，1H)；8.16(m，1H)；8.31(s，1H).NMR-C13(CF3COOD)：9.03；14.20；26.68；38.77；43.98；53.79；58.27；64.73；77.93；106.85；109.24；110.15；128.99；129.20；131.61；137.32；141.23；144.13；154.79；158.32；160.25；160.8?1；179.30.IR(KBr)：1013；1068；1265；1466；1514；1601；1655；1748.

Preparation example 18:5-ethyl-4,5-dihydro-5-hydroxyl-12-methyl isophthalic acid H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

Use preparation example 17.b., 17.c. and the described method of 17.d. and prepare 2-chloro-4-methyl-3-quinoline methanol with 2-ethanoyl aniline.According to the method for preparation example 4 step 4.j. with the latter and compound (M) coupling.The gained coupling product is according to the described method cyclization of step 4.k..Obtain yellow solid, m.p.＞260 ℃.NMR?1H(DMSO)：0.87(t，3H)；1.87(q，2H)；2.78(s，3H)；2.80(d，1H)；3.55(d，1H)；5.27(s，2H)；5.42(d，1H)；5.52(d，1H)；6.04(s，1H)；7.39(s，1H)；7.75(t，1H)；7.88(t，1H)；8.13(d，1H)；8.25(d，1H).NMR-C13(DMSO)：8.23；36.26；42.36；62.00；73.11；78.65；79.13；79.25；99.52；122.36；124.30；127.67；129.54；129.55；129.56；140.11；145.06；148.07；152.00；155.79；159.09；171.89.IR(KBr)：1649；1751；3404.

Preparation example 19:10-benzyloxy-5-ethyl-9-fluoro-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

Use the described method of preparation example 4.i. and prepare 2-chloro-7-fluoro-6-methoxyl group-quinoline-3-formaldehyde, the latter was handled 24 hours with the excessive boron tribromide that is in the methylene dichloride in room temperature with 3-fluoro-4-methoxyl group-ethanoyl aniline.Thereby gained 2-chloro-7-fluoro-6-hydroxyl-quinoline-3-formaldehyde is carried out O-benzylization preparation 6-benzyloxy-2-chloro-7-fluoro-quinoline-3-formaldehyde in dimethyl formamide, its reduction is prepared corresponding quinoline methanol in the presence of bromotoluene and salt of wormwood with the sodium borohydride in the methyl alcohol.Described according to preparation example 4 step 4.j. with the latter and compound (M) coupling.The gained coupling product is according to the described method cyclization of step 4.k..Obtain yellow solid, m.p.＞275 ℃.NMR-1H(DMSO)：0.86(t，3H)；1.85(q，2H)；3.05(d，1H)；5.25(s，2H)；5.37(s，2H)；5.45(dd，2H)；6.05(s，1H)；7.4-7.6(m，5H)；7.88(d，1H)；7.95(d，1H)；8.56(s，1H).

Preparation example 20:5-ethyl-9-fluoro-4,5-dihydro-5,10-dihydroxyl-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

The compound (0.79mmol) of preparation example 19 is dissolved in the trifluoroacetic acid (15ml), makes catalyst treatment with 10% palladium/carbon (60mg) with hydrogen.Obtain yellow solid, m.p.＞275 ℃.NMR-1H(DMSO)：0.86(t，3H)；1.85(q，2H)；3.05(d，1H)；5.25(s，2H)；5.37(s，2H)；5.45(dd，2H)；6.05(s，1H)；7.8(d，1H)；7.90(d，1H)；8.56(s，1H).

Above-mentioned preparation example is as by following embodiment basis of the present invention being described.

Embodiment 1:

5-ethyl-9,10-two fluoro-4,5-dihydro-5-(2-amino-1-oxo oxyethyl group)-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

A. 5-ethyl-9,10-two fluoro-4,5-dihydro-5-(2-(t-butoxycarbonyl amino)-1-oxo oxyethyl group)-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-dione hydrochloride

With 5-ethyl-9,10-two fluoro-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone (200mg, 0.526mmol, derive from preparation example 4), N-Boc-glycine (185mg, 1.051mmol) and the mixture of catalytic amount 4-dimethylaminopyridine (20mg) in anhydrous pyridine (10ml), under 0 ℃ and argon atmospher, with dicyclohexylcarbodiimide (239mg, 1.16mmol) handle, stirring at room is 48 hours then.Vacuum is removed volatile matter and this resistates is carried out chromatogram (silicon-dioxide, the chloroformic solution of 1% methyl alcohol) purifying, obtains required intermediate (40mg, 14%), is yellow solid.NMR-1H(CDCl ₃)：1.20(t，3H)；1.38(s，9H)；1.40-1.70(m，2H)；3.10(d，1H)；4.00(d，2H)；4.30(d，1H)；5.00(t，1H)；5.20(s，2H)；5.30-5.90(dd，2H)；7.20(s，1H)；7.50-8.10(m，2H)；8.30(s，1H).

B. 5-ethyl-9,10-two fluoro-4,5-dihydro-5-(2-amino-1-oxo oxyethyl group)-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-dione hydrochloride

(40mg, methylene dichloride 0.072mmol) (10ml) solution remain on 0 ℃ and drip with the saturated De diox of hydrogenchloride (8ml) with the intermediate of above-mentioned acquisition.Formed yellow suspension was stirred 2 hours, and vacuum is removed volatile matter then.This resistates of dissolving in water (5ml) is with methylene dichloride (3 * 30ml) washings.Thereby the salt of this water is freezing and freeze-drying preparation expection is water absorbability yellow solid (20mg, 50%).NMR-1H(CDCl ₃)：1.00(t，3H)；2.15(m，1H)；2.30(m，1H)；3.60(d，1H)；

3.90(d，1H)；4.15(s，2H)；5.10(s，2H)；5.40(d，1H)；5.70(d，2H)；7.40(s，1H)；

7.80(m，2H)；8.50(s，1H).

Embodiment 2:

5-ethyl-9,10-two fluoro-4,5-dihydro-5-(2-amino-1-oxopropoxy)-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone

Method according to embodiment 1; with 5-ethyl-9; 10-two fluoro-4,5-dihydro-5-hydroxyl-1H-oxepin also [3 ', 4 ': 6; 7] indolizino [1; 2-b] and quinoline-3,15 (4H, 13H)-diketone; and, pass through then in methylene dichloride with the Boc protecting group on the trifluoroacetic acid processing fracture intermediate with N-Boc-b-L-Ala replacement N-Boc-glycine.Vacuum-evaporation is fallen volatile matter and this resistates is dissolved in methylene dichloride.With rare supercarbonate washing gained solution, dry and evaporation.Obtain yellow solid.

Use the method for embodiment 1 and 2, can obtain similar result for other compound.Can " prodrug " form obtain all camptothecin analogues like this.

Embodiment 3:

1,8-diethyl-8,9-dihydro-8-hydroxyl-2H, 10H, 12H-[1,3] oxazines also [5,6-f] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone

With 5-ethyl-4,5-dihydro-5,10-dihydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-suspension of diketone (84mg is according to preparation example 5 preparation) in acetate (2.5ml) is with 1,3,5-triethyl Hexahydrotriazine (0.5ml) is handled.This reaction mixture was stirred vacuum-evaporation then 30 minutes at 70 ℃.With this resistates of dissolve with ethanol, filter and wash with ether.Obtain solid, m.p.＞275 ℃.

NMR-1H(DMSO)：0.87(t，3H)；1.50(t，3H)；1.85(q，2H)；2.77(q，2H)；3.05(d，

1H)；3.47(d，1H)；4.37(s，2H)；5.00(s，2H)；5.22(s，2H)；5.45(dd，2H)；6.00(s，

1H)；7.34(s，1H)；7.36(d，1H)；7.93(d，1H)；8.53(s，1H).

NMR-C13(DMSO)：8.46；13.48；36.46；42.49；45.49；46.44；50.75；61.43；73.33；

82.06；99.02；112.90；122.00；122.98；125.42；127.04；129.04；130.20；144.09；

144.97；149.87；152.92；155.98；172.07.

IR(KBr)：1045；1215；1502；1604；1657，1722.

Embodiment 4:

8-ethyl-8,9-dihydro-8-hydroxyl-1-methyl-2H, 10H, 12H-[1,3] oxazines also [5,6-f] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone

With 5-ethyl-4,5-dihydro-5,10-dihydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-suspension of diketone (200mg is according to preparation example 5 preparation) in acetate (5ml) is with six hydrogen-1,3,5-trimethylammonium triazine (110mg) is handled.This reaction mixture was stirred vacuum-evaporation then 30 minutes at 70 ℃.Reclaim this resistates with ethanol, filter and wash with ether.Obtain solid, m.p.＞275 ℃.NMR-1H(DMSO)：0.87(t，3H)；1.85(q，2H)；3.04(d，1H)；3.48(d，1H)；4.33(s，2H)；4.93(s，2H)；5.28(s，2H)；5.45(dd，2H)；6.01(s，1H)；7.35(s，1H)；7.38(d，1H)；7.94(d，1H)；8.49(s，1H).NMR-C13(DMSO)：8.46；36.43；37.85；42.55；48.68；50.79；61.43；73.35；83.82；99.04；112.49；122.04；123.00；125.46；127.14；129.07；130.27；144.99；149.95；152.46；155.99；172.09IR(KBr)：1047；1058；1219；1246；1295，1439；1504；1604，1655，1735.

Embodiment 5:

8-ethyl-8,9-dihydro-8-hydroxyl-1-benzyl-2H, 10H, 12H-[1,3] oxazines also [5,6-f] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone

With 5-ethyl-4,5-dihydro-5,10-dihydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-suspension of diketone (200mg is according to preparation example 5 preparation) in acetate (5ml) is with 1,3,5-tribenzyl Hexahydrotriazine (285mg) is handled.This reaction mixture was stirred vacuum-evaporation then 30 minutes at 70 ℃.Reclaim this resistates with ethanol, filter and wash with ether.Obtain solid, m.p.＞275 ℃.NMR-1H(DMSO)：0.85(t，3H)；1.85(q，2H)；3.05(d，1H)；3.47(d，1H)；3.96(s，2H)；4.33(s，2H)；5.04(s，2H)；5.17(s，2H)；5.44(dd，2H)；6.01(s，1H)；7.38(m，6H)；7.42(d，1H)；7.97(d，1H)；8.42(s，1H).NMR-C13(DMSO)：8.42；19.96；36.45；42.51；46.36；50.78；55.38；61.39；73.31；99.00；112.55；122.01；123.08；125.38；127.09；127.47；128.70；129.14；130.35；128.40；139.19；144.18；149.99：152.84；155.92；159.24；172.05.IR(KBr)：1056；1205；1225；1248；1504；1535；1599；1655；1726.

Embodiment 6:

8-ethyl-8,9-dihydro-4-fluoro-8-hydroxyl-1-benzyl-2H, 10H, 12H-[1,3] oxazines also [5,6-f] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone

With 5-ethyl-9-fluoro-4,5-dihydro-5,10-dihydroxyl-1H-oxepin also [3 ', 4 ': 6,7]-indolizino [1,2-b] quinoline-3,15 (4H, 13H)-suspension of diketone (200mg is according to preparation example 20 preparation) in acetate (5ml) is with 1,3,5-tribenzyl Hexahydrotriazine (285mg) is handled.This reaction mixture was stirred vacuum-evaporation then 30 minutes at 70 ℃.Reclaim this resistates with ethanol, filter and wash with ether.Obtain solid, m.p.＞250 ℃.NMR-1H(DMSO)：0.85(t，3H)；1.85(q，2H)；3.05(d，1H)；3.48(d，1H)；3.95(s，2H)；4.45(s，2H)；5.20(s，4H)；5.45(dd，2H)；6.05(s，1H)；7.40(s，7H)；7.90(d，1H)；8.45(s，1H).IR(KBr)：1248；1451；15001；1598；1657；1727.

The pharmacology research of product of the present invention

The relaxation activity experiment of topoisomerase 1 inductive DNA

All are reflected in the 20 μ l reaction buffers carries out, this damping fluid is by 50mM Tris-HCl (pH7.5), 50mM Repone K, 0.5mM dithiothreitol (DTT), 10mM magnesium chloride, 0.1mM ethylenediamine tetraacetic acid (EDTA) (EDTA), 30 μ g/ml fetal bovine serum albumin and 300ng superhelix pUC19 (Pharmacia Biotech, Orsay, France) form, wherein do not add or add the test compound of fixed concentration.All test compounds begin all to be dissolved in the dimethyl sulfoxide (DMSO) (DMSO) or are applicable to and carry out other dilution with distilled water in the water of water-soluble cpds.The ultimate density of DMSO is no more than 1% (v/v).(UnitedKingdom) initiation reaction makes after 15 minutes to react completely for Life Technologies/Gibco-BRL, Paisley at the DNA topoisomerase 1 of 37 ℃ of calf thymuss by adding purifying.Contain 1% sodium lauryl sulphate, 20mM EDTA and 500 μ g/ml K protein kinase (BoehringerMannheim, Meylan, mixture stopped reaction France) by adding 3 μ l.37 ℃ hatch 30 minutes again after, in sample, add 2 μ l sample loading buffers, this damping fluid contains 10mM Sodium phosphate dibasic, 0.3% tetrabromophenol sulfonphthalein and 16%Ficoll, this sample was carried out electrophoresis 20 hours with 1V/cm in damping fluid on 1.2% agar gel, wherein this damping fluid contains 36mMTris-HCl (pH7.8), 30mM Sodium phosphate dibasic, 1mM EDTA and 2 μ g/ml chloroquines.With 2 μ g/ml ethidium bromides that this is gel-colored, under UV light, take pictures with charge-coupled instrument (ccd) photographic camera at 312nm, and with bioProfil imaging analysis instrument (Viber Lourmat, Lyon, France) fluorescence intensity is with the percentage of definite DNA that discharges.

In each experiment, the super spirial plasmid dna single solely or with topoisomerase 1 is cultivated.In 15 minutes, finish this reaction.For each test compound or contrast (contrast that is called that will only contain carrier), this super spirial plasmid DNA experiment at test compound or contrast when not having enzyme is hatched with under the peak concentration, when perhaps having enzyme test compound with 1 μ M to 200 μ M concentration in the presence of or in the presence of contrast, hatch.As shown in Table I, embodiment 3 to 6 suppresses the activity of loosening that topoisomerase 1 causes in concentration dependence mode.

Table 1

	Micro-molar concentration
					????10	????50	????100	????200
	Embodiment
Camptothecine					????88.7	????62.4	????52.9	????46.9
	????3	????79.7	????46.9	????33.5					????23.2
????4					????86.2	????32.7	????35.1	????32.1
	????5	????56.2	????30.4	????28.0					????24.2
????6					????55.6	????39.9	????38.9	????30.0

Claims (16)

1. the analogue of a camptothecine, wherein the hydroxy-lactone of camptothecine is beta-hydroxy lactone or the corresponding beta-hydroxy acid that obtains of lactone open loop thus, it is characterized in that described analogue contains the oxazine ring that can be replaced on 10 and 11 that are connected on the A ring.

2. the analogue of a camptothecine, the hydroxy-lactone that it is characterized in that camptothecine by by the B-hydroxy-lactone of the radical protection that is easy to rupture or thus the corresponding beta-hydroxy acid that obtains of lactone open loop replace.

3. compound is characterized in that described compound is any mixture or its pharmaceutical salts of formula (I) or formula (II), its racemic modification or enantiomeric forms or these forms:

R ₁Expression low alkyl group, low-grade alkenyl, alkynyl of low-grade chain, low-grade halogenated alkyl, lower alkoxy low alkyl group or lower alkylthio low alkyl group;

R ₂, R ₃And R ₄Represent H, halogen, low-grade halogenated alkyl, low alkyl group, low-grade alkenyl, cyano group, rudimentary cyano group alkyl, nitro, rudimentary 4-nitro alkyl, amido, rudimentary amidoalkyl, diazanyl, rudimentary diazanyl alkyl, azido-, rudimentary azido-alkyl, (CH independently ₂) _mNR ₆R ₇, (CH ₂) _mOR ₆, (CH ₂) _mSR ₆, (CH ₂) _mCO ₂R ₆, (CH ₂) _mNR ₆C (O) R ₈, (CH ₂) _mC (O) R ₈, (CH ₂) _mOC (O) R ₈, O (CH ₂) _mNR ₆R ₇, OC (O) NR ₆R ₇, OC (O) (CH ₂) _mCO ₂R ₆Or (CH ₂) _n[N=X], OC (O) [N=X], (CH ₂) _mOC (O) [N=X] (in the present invention, 4 to 7 yuan of heterocyclic radicals of [N=X] expression nitrogen atom N, N is an atom of heterocyclic group, and X represents to constitute all the other atoms of these heterocycle needs, and they are selected from O, S, CH ₂, CH, N, NR ₉And COR ₁₀), do not replace or be substituted the aryl or the lower aryl alkyl of (promptly replace one to four time) on aryl or heterocycle, wherein substituting group is low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group, perhaps R ₃And R ₄Form 3 or 4 yuan chain together, wherein the element of this chain is selected from CH, CH ₂, O, S, N or NR ₉

R ₅Expression H, halogen, low-grade halogenated alkyl, low alkyl group, lower alkoxy, lower alkoxy low alkyl group, lower alkylthio low alkyl group, cycloalkyl, cycloalkyl low-grade alkyl, cyano group, cyano group alkyl, the rudimentary alkylsulfonyl alkyl of low alkyl group, rudimentary hydroxyalkyl, nitro, (CH ₂) _mC (O) R ₈, (CH ₂) _mNR ₆C (O) R ₈, (CH ₂) _mNR ₆R ₇, (CH ₂) _mN (CH ₃) (CH ₂) _nNR ₆R ₇, (CH ₂) _mOC (O) R ₈, (CH ₂) _mOC (O) NR ₆R ₇, (CH ₂) _mS (O) _qR ₁₁, (CH ₂) _mP (O) R ₁₂R ₁₃, (CH ₂) ₂P (S) R ₁₂R ₁₃Or (CH ₂) _n[N=X], OC (O) [N=X], (CH ₂) _mOC (O) [N=X], do not replace or substituted (promptly replacing one to four time on aryl or heteroaryl) aryl or lower aryl alkyl, wherein substituting group is low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

R ₆And R ₇Represent H, low alkyl group, rudimentary hydroxyalkyl, the rudimentary aminoalkyl group of low alkyl group, rudimentary aminoalkyl group, cycloalkyl, cycloalkyl low-grade alkyl, low-grade alkenyl, lower alkoxy low alkyl group, low-grade halogenated alkyl independently or be substituted (promptly replacing one to four time) or unsubstituted aryl or lower aryl alkyl on aryl, wherein substituting group is low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

R ₈Represent H, low alkyl group, rudimentary hydroxyalkyl, amino, low-grade alkyl amino, the rudimentary aminoalkyl group of low alkyl group, rudimentary aminoalkyl group, cycloalkyl, cycloalkyl low-grade alkyl, low-grade alkenyl, lower alkoxy, lower alkoxy low alkyl group, low-grade halogenated alkyl or be substituted (promptly replacing one to four time) or unsubstituted aryl or lower aryl alkyl on aryl, wherein substituting group is low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

R ₉Expression H, low alkyl group, low-grade halogenated alkyl, aryl or the aryl that is replaced by following one or more groups: low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group;

R ₁₀Expression H, low alkyl group, low-grade halogenated alkyl, lower alkoxy, aryl or the aryl (one to four substituting group is promptly arranged on aryl) that is replaced by one or more groups, substituting group is selected from low alkyl group, low-grade halogenated alkyl, rudimentary hydroxyalkyl or lower alkoxy low alkyl group;

R ₁₁Expression low alkyl group, aryl, (CH ₂) _mOR ₁₄, (CH ₂) _mSR ₁₄, (CH ₂) ₂NR ₁₄R ₁₅Or (CH ₂) _m[N=X];

R ₁₂And R ₁₃Represent low alkyl group, aryl, lower alkoxy, aryloxy or amino independently;

R ₁₄And R ₁₅Represent H, low alkyl group or aryl independently;

R ₁₆Expression H or OR ₂₁

R ₁₇Expression OR ₆Or NR ₆R ₇

R ₁₈And R ₁₉Represent H, halogen, low alkyl group, lower alkoxy or hydroxyl independently;

R ₂₀Expression H or halogen;

R ₂₁Expression H, low alkyl group, CHO or C (O) (CH ₂) _mCH ₃

R _pRepresent H or be easy to the cracked group, preferably corresponding to formula-C (O)-A-NR ₂₂R ₂₃Group, wherein A represents the straight or branched alkylidene group, this alkylidene group can be selected from free, esterification or salifiable hydroxyl, halogen, carboxyl free, esterification or salifiable, amino, list or dialkyl amido replace, and R ₂₂And R ₂₃Represent H, low alkyl group, rudimentary hydroxyalkyl, the rudimentary aminoalkyl group of low alkyl group, rudimentary aminoalkyl group, cycloalkyl, cycloalkyl low-grade alkyl, low-grade alkenyl, lower alkoxy low alkyl group, low-grade halogenated alkyl independently or do not replace or replace the aryl or the lower aryl alkyl of (one to four substituting group is promptly arranged) on aryl, substituting group is selected from low alkyl group, halogen, nitro, amino, low-grade alkyl amino, low-grade halogenated alkyl, rudimentary hydroxyalkyl, lower alkoxy or lower alkoxy low alkyl group or R ₂₂With R ₂₃Form together can contain that another that be selected from O, N, S is heteroatomic can substituted 5,6 or 7 Yuans rings;

M is the integer between 0 to 6;

N is 1 or 2; And

Q represents 0 to 2 integer; And

[N=X] represents 4 to 7 yuan of heterocyclic radicals, and X represents to constitute the chain of described heterocyclic radical needs and is selected from O, S, CH ₂, CH, N, NR ₉And COR ₁₀

Condition is to work as R _pWhen being hydrogen atom, R ₃And R ₄Form 3 or 4 yuan chain together.

4. the compound or pharmaceutically acceptable salt thereof of claim 3 is characterized in that R ₁The expression ethyl.

5. the described compound or pharmaceutically acceptable salt thereof of claim 3 is characterized in that R ₅Expression H, low alkyl group or (CH ₂) _mNR ₆R ₇Or (the CH that is not substituted or is replaced by low alkyl group ₂) _n[N=X].

6. the described compound or pharmaceutically acceptable salt thereof of claim 3 is characterized in that R ₃And R ₄But form Bei and replace De oxazine ring.

7. the described compound or pharmaceutically acceptable salt thereof of claim 3 is characterized in that R _pBe to be easy to the cracked group.

8. the described compound or pharmaceutically acceptable salt thereof of claim 7 is characterized in that R _pExpression C (O)-(A ₁)-N-R ₂₂-R ₂₃Group, wherein A ₁Expression CH _2mOr the side chain low-grade alkylidene, and m is the integer between the expression 0 to 6.

9. the compound or pharmaceutically acceptable salt thereof of claim 6 is characterized in that described compound is selected from:

-1,8-diethyl-8,9-dihydro-8-hydroxyl-2H, 10H, 12H-[1,3] oxazines also [5,6-f] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone

-8-ethyl-8,9-dihydro-8-hydroxyl-1-methyl-2H, 10H, 12H-[1,3] oxazines also [5,6-f] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone

-8-ethyl-8,9-dihydro-8-hydroxyl-1-benzyl-2H, 10H, 12H-[1,3] oxazines also [5,6-f] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone

-8-ethyl-8,9-dihydro-4-fluoro-8-hydroxyl-1-benzyl-2H, 10H, 12H-[1,3] oxazines also [5,6-f] oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-10,13 (15H)-diketone.

10. the compound or pharmaceutically acceptable salt thereof of claim 7 is characterized in that described compound is selected from:

-5-ethyl-9,1O-two fluoro-4,5-dihydro-5-(2-amino-1-oxo oxyethyl group)-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone;

-5-ethyl-9,10-two fluoro-4,5-dihydro-5-(2-amino-1-oxopropoxy)-1H-oxepin also [3 ', 4 ': 6,7] indolizino [1,2-b] quinoline-3,15 (4H, 13H)-diketone.

11. the described compound or pharmaceutically acceptable salt thereof of above-mentioned arbitrary claim is as the purposes of medicine.

12. pharmaceutical composition wherein contains at least a claim 1 to 10 each described compound as activeconstituents.

13. the purposes of each described compound of claim 1 to 10 in the preparation antitumor drug.

14. each is described corresponding to R wherein in the claim 1,6 and 9 ₃And R ₄The preparation method of the compound of the formula Ia of the formula I product of Xing Cheng oxazine ring is characterized in that:

-with the β hydroxy-lactone compound of general formula D:

R wherein ₃Be hydroxyl, R ₄Be H and R ₁, R ₂, R ₁₈, R ₁₉And R ₂₀Definition is as above handled under the Mannich reaction conditions to obtain the beta-hydroxy lactone compound of the logical Ia of formula with primary amine

R wherein ₁, R ₂, R ₅, R ₉, R ₁₈, R ₁₉And R ₂₀Definition as above.

15. each is described corresponding to R wherein in the claim 2 to 10 _pNot the preparation method of formula Ib compound of the formula I product of hydrogen atom, it is characterized in that:

The compound of-general formula D

Or

Preferably use the described C of claim 3 (O)-A-N-R ₂₂R ₂₃The derivative acidylate of group is with preparation R _pIt or not the beta-hydroxy lactone compound of the general formula I of H.

16. the preparation method of each described formula II compound in the claim 1 to 10 is characterized in that:

Thereby-in alkaline medium with the compound of lactone open loop preparation formula II after neutralization of general formula I

R wherein ₁, R ₂, R ₅, R ₉, R ₁₇, R ₁₈, R ₁₉And R ₂₀Definition as above; R ₁₆Expression OR ₂₁, R wherein ₂₁Expression H or low alkyl group; And R ₁₇Expression OR ₆Or NHR ₆, and R ₆Expression H, low alkyl group, cycloalkyl, low alkyl group cycloalkyl, low-grade alkenyl, low alkyl group lower alkoxy or aryl or low-grade alkylaryl.